You are here

Article metrics

Article menu

Download PDFPDF

Research Article
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to April 2025

AbstractFullPdf
Dec 2019110
Jan 2020992
Feb 202025255
Mar 202024249
Apr 202016162
May 202035353
Jun 2020616112
Jul 202030307
Aug 2020484833
Sep 2020464612
Oct 2020646411
Nov 20201451455
Dec 202048485
Jan 2021868627
Feb 2021737319
Mar 202110710727
Apr 2021636323
May 2021929429
Jun 202121021329
Jul 202128028031
Aug 2021656517
Sep 202113213122
Oct 2021989839
Nov 2021727229
Dec 2021566015
Jan 2022565714
Feb 2022494915
Mar 202213314121
Apr 2022889019
May 2022848421
Jun 2022818619
Jul 2022959825
Aug 20229810120
Sep 2022778019
Oct 2022808010
Nov 202211411622
Dec 2022666813
Jan 2023747416
Feb 2023767619
Mar 202359617
Apr 2023616320
May 2023666712
Jun 2023788016
Jul 2023737411
Aug 202367679
Sep 202350509
Oct 202357578
Nov 2023939321
Dec 2023828313
Jan 2024545517
Feb 2024484815
Mar 2024969671
Apr 202415215326
May 2024858535
Jun 2024666519
Jul 2024495015
Aug 2024484810
Sep 2024636311
Oct 2024606017
Nov 2024888915
Dec 2024979919
Jan 202510110113
Feb 2025848420
Mar 2025525215
Apr 202512112220
Total500750591130